Publicaties

Laboratory investigations are important in the clinical management and the study of chronic kidney disease-mineral and bone disorder (CKD-MBD)- including CKD-associated osteoporosis. Parathyroid hormone (PTH) is the major hormone in the regulation of bone and calcium balance but is significantly affected in advanced CKD. Knowledge of PTH concentration is important in the assessment of osteoporosis including CKD-associated osteoporosis; however, ...

INTRODUCTION: Bone disease after kidney transplantation is complex, converging features of senile, postmenopausal, glucocorticoid-induced, and chronic kidney disease (CKD)-associated osteoporosis. CASE PRESENTATION: We present a case of a 60-year-old female kidney transplant recipient with osteoporosis, who failed to show an improvement in areal bone mineral density (aBMD) after 5 years of annual intravenous therapy with 5 mg zoledronate. After ...

BACKGROUND: Chronic kidney disease (CKD) is associated with disturbances in mineral and bone metabolism, increasing fracture risk, particularly in advanced stages. Bone turnover markers (BTMs) such as bone alkaline phosphatase (BALP) and tartrate-resistant acid phosphatase 5b (TRACP5b), as well as collagen-derived markers including intact form of procollagen type I amino-terminal propeptide (iPINP) and β-cross-linked C-terminal telopeptide of ...

When kidney function is compromised, myriad metabolites and peptides - uraemic retention molecules (URMs) - accumulate in the body and compromise homeostasis. Over 150 molecules have been classified as URMs but omics approaches are revealing many more. When URMs exert pathophysiological effects and/or are associated with relevant adverse patient outcomes, they are called uraemic toxins. The origins of uraemic toxins and their contributions to ...

PURPOSE OF REVIEW: To discuss current evidence on the diagnosis and management of osteoporosis in patients with chronic kidney disease (CKD). RECENT FINDINGS: Osteoporosis and fractures are prevalent in older CKD patients and associated with poor process indicators and outcomes. While osteoporosis treatment is generally similar in patients without or with CKD up to stage 3, there is still a lack of evidence to guide many areas of osteoporosis ...

Besides the well-known role of hormonal factors in mineral and bone metabolism, the sympathetic nervous system participates in this regulation by inhibiting bone formation and promoting bone resorption, primarily via β-adrenergic receptors expressed on osteoblasts. Conversely, the parasympathetic system, through cholinergic signalling, inhibits osteoclast activity, promoting bone formation and maintaining skeletal homeostasis. This review ...